文献速递类风湿关节炎

丹麦登记研究:类风湿关节炎患者全髋或全膝关节置换术后内科并发症风险

Risk of medical complications following total hip or knee arthroplasty in patients with rheumatoid arthritis: A register-based cohort study from Denmark.
PubMed 文献 · Semin Arthritis Rheum · 2019-06-13

基于丹麦全国登记数据,纳入2000–2015年接受全髋或全膝关节置换的2899例类风湿关节炎(RA)和112571例骨关节炎(OA)患者,随访术后90天。生物制剂治疗者感染和VTE风险数值上更高,但部分估计不精确。

要点

  • RA患者全髋/全膝关节置换术后感染风险较OA升高(HR 1.29)。
  • RA患者全膝关节置换后VTE风险较OA降低(HR 0.60)。
  • 生物制剂治疗RA患者VTE风险较未用生物制剂者升高(HR 4.82)。

核心结论

  • RA是全髋/全膝关节置换术后感染的危险因素。
  • 生物制剂治疗RA患者感染风险较未用生物制剂者略有升高。
  • RA患者术后VTE风险较OA低,但生物制剂治疗者VTE发生率升高需进一步研究。

研究设计与样本

  • 丹麦全国登记队列研究,纳入2000–2015年接受全髋或全膝关节置换的RA和OA患者。
  • RA 2899例,OA 112571例,随访术后90天。
  • 生物制剂治疗信息来自DANBIO风湿病登记,与非生物制剂治疗RA患者比较。

主要发现

  • 生物制剂治疗者心肌梗死/卒中发生比例1.0% vs 非生物制剂者0.6%,但事件数太少无法估计HR。

临床怎么用

  • RA患者全髋/全膝关节置换术后应关注感染风险。
  • 使用生物制剂的RA患者围手术期需关注VTE风险。

局限性

  • 生物制剂治疗者心肌梗死/卒中事件数太少,无法估计HR。
  • 生物制剂治疗者VTE风险估计基于有限事件,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the risk of medical complications following total hip and knee arthroplasty (THA/TKA) among rheumatoid arthritis (RA) compared with osteoarthritis (OA) patients; and, to assess the risk of complications among biologics-treated RA patients. METHODS: In a nationwide register-based study, patients with RA and OA with THA/TKA surgery between 2000 and 2015 were identified and followed up to 90 days after surgery for venous thromboembolism (VTE), myocardial infarction and stroke, and non-surgical infections, respectively. Information on treatment with biologics was obtained in the DANBIO rheumatology register to compare risks of complications with non-biologics treated. RESULTS: A total of 2899 and 112,571 patients with RA and OA had THA/TKA. RA was associated with a hazard ratio (HR) of 1.29 (1.03 to 1.61) for infection following THA/TKA, but a HR of 0.60 (0.26 to 0.98) for VTE following TKA. Biologics treated patients had a HR of 1.35 (0.65 to 2.80) for infection and 4.82 (1.67 to 13.90) for VTE compared with non-biologics treated RA patients. RA patients had no increased risk of post-surgical myocardial infarction and stroke (HR 1.16, 0.76 to 1.78) compared with OA, but a higher incidence proportion was observed in biologics treated compared with non-biologics treated (1.0% vs 0.6%); however, the number of events were too small to estimate a HR. CONCLUSION: In this study, RA was a risk factor for infection after THA/TKA, and RA patients treated with biologics had a slightly increased risk compared with non-biologics treated RA patients. Compared with OA, RA patients had a lower risk of VTE following THA/TKA, but our finding of increased incidences of VTE in biologics-treated patients warrants further studies.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Cordtz R, Odgaard A, Kristensen LE, et al. Risk of medical complications following total hip or knee arthroplasty in patients with rheumatoid arthritis: A register-based cohort study from Denmark. Semin Arthritis Rheum. 2019. PMID: 31272806. doi:10.1016/j.semarthrit.2019.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。